Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 206

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 206
---
 of our Ordinary Shares and could impair our future ability
to obtain capital, especially through an offering of equity securities. Assuming that the underwriters do not exercise in full their
option to purchase additional Ordinary Shares and/or additional Warrants with respect to this offering and assuming no exercise of options
outstanding following this offering, we will have an aggregate of Ordinary Shares outstanding upon the closing of this offering. Of these
shares, the Ordinary Shares sold in this offering will be freely tradable without restriction or further registration under the Securities
Act, unless purchased by “affiliates” (as that term is defined under Rule 144 of the Securities Act, or Rule 144),
who may sell only the volume of shares described below and whose sales would be subject to additional restrictions described below.

The remaining Ordinary Shares
will be held by our existing shareholders and will be deemed to be “restricted securities” under Rule 144. Subject to
certain contractual restrictions, including the lock-up agreements described below, restricted securities may only be sold in the public
market pursuant to an effective registration statement under the Securities Act or pursuant to an exemption from registration under Rule 144,
Rule 701 or Rule 904 under the Securities Act. These rules are summarized below. Sales of these shares in the public market
after the restrictions under the lock-up agreements lapse, or the perception that those sales may occur, could cause the prevailing market
price of our Ordinary Shares to decrease or to be lower than it might be in the absence of those sales or perceptions.

Eligibility of Restricted Shares for Sale in the Public Market

Approximately 3,929,378 of
our Ordinary Shares will be eligible for resale pursuant to Rule 144 after 90 days following the pricing of this offering as
follows:

| ● | with respect to non-affiliates                                                                                                          
 of our company who will hold an aggregate of 2,137,322 Ordinary Shares upon the consummation of this offering, following the expiration 
 of a non-affiliate’s six-month holding period and subject to our compliance with the current public information requirements            
 under Rule 144; and                                                                                                                     |

| ● | with respect to affiliates                                                                                                              
 of our company who will hold an aggregate of 1,792,056 Ordinary Shares upon the consummation of this offering, following the expiration 
 of an affiliate’s six-month holding period and subject to our compliance with the current public information requirements under         
 Rule 144, and subject to the volume, manner of sale and other limitations